Immunovant
IMVT
40 hedge funds and large institutions have $194M invested in Immunovant in 2020 Q1 according to their latest regulatory filings, with 21 funds opening new positions, 8 increasing their positions, 7 reducing their positions, and 5 closing their positions.
320% more first-time investments, than exits
New positions opened: 21 | Existing positions closed: 5
67% more funds holding
Funds holding: 24 → 40 (+16)
14% more repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 7
10% more capital invested
Capital invested by funds: $176M → $194M (+$17.3M)
2.64% more ownership
Funds ownership: 20.58% → 23.21% (+2.6%)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MP
Mangrove Partners
Greenwich,
Connecticut
|
+$7.1M |
| 2 |
Millennium Management
New York
|
+$6.88M |
| 3 |
IC
Ikarian Capital
Dallas,
Texas
|
+$5.09M |
| 4 |
BlackRock
New York
|
+$4.56M |
| 5 |
RSCM
Rock Springs Capital Management
Baltimore,
Maryland
|
+$3.76M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Athanor Capital
New York
|
-$7.93M |
| 2 |
SCM
Sio Capital Management
New York
|
-$7.54M |
| 3 |
GPCM
Granite Point Capital Management
Boston,
Massachusetts
|
-$2.78M |
| 4 |
PM
Prosight Management
Dallas,
Texas
|
-$1.55M |
| 5 |
GTC
Ghost Tree Capital
New York
|
-$1.35M |
IMVT Hedge Fund Activity: Q1 2020 in Review
40 of the 4,538 institutional investors tracked by Wall St. Rank reported a position in Immunovant (IMVT) for Q1 2020, worth a combined $194M — up 9.8% from $176M a quarter earlier.
Buyers outnumbered sellers: 21 funds opened new IMVT positions and 5 closed out — a net gain of 16 holders — while 8 added to existing stakes and 7 trimmed.
The largest buyer was Mangrove Partners, adding an estimated $7.1M. The largest seller was Athanor Capital, exiting entirely with an estimated $7.93M sold.
- 40 institutional investors held Immunovant (IMVT) as of Q1 2020, up from 24 in Q4 2019.
- Funds reported $194M of Immunovant stock for Q1 2020, up 9.8% quarter-over-quarter.
- 21 funds opened new Immunovant positions in Q1 2020 and 5 closed out, a net change of +16 holders.
- The largest Immunovant buyer in Q1 2020 was Mangrove Partners, an estimated $7.1M added.
- The largest Immunovant seller in Q1 2020 was Athanor Capital, an estimated $7.93M sold.
Based on aggregated 13F filings for Q1 2020.